

available at www.sciencedirect.comjournal homepage: www.eu-openscience.europeanurology.com

European Association of Urology



Brief Correspondence

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma

Christian D. Fankhauser^{a,†}, Abolghassem Jandari^{b,†}, Laurence Collette^b, Torgrim Tandstad^c, Di Maria Jiang^d, Ugo De Giorgi^{e,f}, Christopher Sweeney^g, Angelika Terbuch^h, Michal Chovanecⁱ, Robert Huddart^j, Carsten Bokemeyer^k, Jörg Beyer^{l,*}, Silke Gillissen^{m,n}

Article info

Article history:

Accepted August 23, 2023

Associate Editor:

M. Carmen Mir

Keywords:

Germ cell cancer
Tumor biomarker
Treatment outcome
Prognosis

Abstract

Levels of the serum tumor markers (STMs) α -fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are used in staging classification for metastatic germ-cell cancers and support decisions on the intensity of first-line treatment for patients with nonseminoma. Use of preorchiectomy instead of prechemotherapy STM levels can lead to inadequate classification. We identified 744 men with metastatic gonadal nonseminoma in the International Germ-Cell Cancer Collaborative Group (IGCCCG) Update Consortium database who had preorchiectomy and prechemotherapy STM levels available. Of these, 22% would have had inadequate IGCCCG prognostic group classification if preorchiectomy levels had been used, which would have resulted in overtreatment of 16% and undertreatment of 6% of men. These findings suggest that use of preorchiectomy instead of prechemotherapy STM results may lead to incorrect IGCCCG classification, which could compromise treatment success or expose patients to unnecessary toxicity.

Patient summary: For men with testicular cancer, levels of tumor markers in their blood are used when making decisions on chemotherapy intensity. Use of test results for samples taken before removal of the cancer-bearing testicle instead of immediately before chemotherapy can lead to inadequate treatment recommendations.

© 2023 Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Approximately half of patients with testicular germ-cell cancer (GCC) have metastatic disease at initial diagnosis or during follow-up. In 1997, the International Germ-Cell Cancer Collaborative Group (IGCCCG) published a prognostic classification system based on histology, primary tumor

location, extent of metastatic spread, and levels of the serum tumor markers (STMs) α -fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) [1]. In 2021, the IGCCCG Update Consortium validated the original IGCCCG criteria and identified older age,

[†] Joint first authors.



the presence of lung metastases in nonseminoma, and LDH more than 2.5 times the upper limit of normal in seminoma as additional unfavorable prognostic variables [2,3].

The IGCCCG classification is important not only for informing patients and physicians about prognosis but also for deciding on the type and number of chemotherapy cycles. Men in the IGCCCG good prognostic group are treated with three cycles of bleomycin, etoposide, and cisplatin (BEP) or four cycles of etoposide and cisplatin (EP). Patients in the more adverse IGCCCG intermediate or poor prognostic groups require at least four cycles of BEP or have bleomycin replaced by ifosfamide. Allocation of the correct IGCCCG prognostic group is therefore critical to avoid both overtreatment and undertreatment. Any overtreatment would lead to unnecessary side effects. Undertreatment may impair a patient's oncological outcome.

There is wide consensus that use of preorchidectomy instead of prechemotherapy STM levels can lead to such incorrect assignment of a patient's IGCCCG prognostic group. However, there are few data so far to support this consensus and to quantify the potential risk of misclassification. The aim of this retrospective analysis using data from the IGCCCG Update Consortium was to quantify the proportion of IGCCCG group reclassifications that would have occurred if preorchidectomy STM results had been used instead of prechemotherapy STMs as recommended by international guidelines [2,3].

We selected patients with metastatic GCC with testicular primary tumors from the IGCCCG Update database. Patients in the IGCCCG database underwent first-line chemotherapy with at least three cycles of cisplatin-based chemotherapy. Only patients with nonseminomatous or mixed testicular GCC without nonpulmonary visceral metastases (NPVM) for whom preorchidectomy and postorchidectomy STM data were available were included in the analysis. Seminomas with elevated AFP were classified as nonseminoma. Pure seminomas without AFP elevation were excluded. Patients who received chemotherapy >90 d after orchidectomy were considered as having metachronous disease after surveillance and were also excluded. Progression-free survival (PFS) was defined as time from the start of chemotherapy to disease progression, death, or last follow-up. Overall survival (OS) was defined as time from the start of chemotherapy to death or last follow-up. Patients lost to follow-up were censored at the date of last contact.

Of the total population of 9575 men, only 744 met the eligibility criteria for our study. The primary reason for exclusion was lack of information necessary for calculating the preorchidectomy IGCCCG prognostic group from 21 of 30 participating institutions (Supplementary material). Median follow-up from the start of chemotherapy to either death or loss to follow-up ($n = 9575$; 1351 events) was estimated using the reverse Kaplan-Meier method as 5.35 yr (interquartile range [IQR] 2.58–9.55). There were notable differences between the included and excluded groups (Supplementary material). Patients who were included had lower median AFP (30.1 vs 43.4 ng/ml) and HCG (48.0 vs 68.0 U/l) levels before orchidectomy. In addition, the eligible patients had better PFS and OS in comparison to the patients who were excluded (Supplementary material). However, as this was an unplanned retrospective analysis and as patients with NPVM and primary mediastinal nonseminoma had to be excluded from the analysis, these results were expected. Furthermore, it is important to highlight that only a small percentage of the eligible group (2.2%) consisted of patients from trials, whereas a significant proportion of the ineligible group (25.4%) were participants in clinical trials.

We finally included 744 men with a median age of 29 yr (IQR 24–35) fulfilling the inclusion criteria, of whom 449 (60%) had good, 237 (32%) had intermediate, and 58 (8%) had poor IGCCCG prognosis. The median time from orchidectomy to chemotherapy was 26 d (IQR 16–40). At 3 yr, the PFS and OS rates for the overall cohort were 87% and 93%, respectively. If preorchidectomy instead of prechemotherapy STM results had been used, assignment of the IGCCCG prognostic group would have been incorrect for 169/744 patients (22%; Table 1), while no change in IGCCCG group would have been observed for 575/744 patients (78%). Higher IGCCCG classification leading to overtreatment would have occurred for 122/44 patients (16%). Lower IGCCCG classification leading to undertreatment would have occurred for 47/744 patients (6%). The P-B κ value was 0.6593 (95% confidence interval [CI] 0.6141–0.7044).

As expected, among the cohort of 575 men without a change in IGCCCG prognosis group, a better PFS rate at 3 yr was observed for the good prognosis group (93.8%, 95% CI 90.6–95.9%) than for the IGCCCG intermediate/poor prognosis group (82.3%, 95% CI 77.1–86.4%). Owing to the

Table 1 – Reclassification of the IGCCCG prognosis group if preorchidectomy results (column 1) were used instead of prechemotherapy results (columns 2–4)^a

<i>Preorchidectomy</i>	<i>Prechemotherapy, n (%)</i>			<i>Total</i>
	<i>Good</i>	<i>Intermediate</i>	<i>Poor</i>	
<i>Good</i>	342 (46)	31 (4)	1 (0.1)	374 (50)
<i>Intermediate</i>	97 (13)	191 (26)	15 (2)	303 (41)
<i>Poor</i>	10 (1)	15 (2)	42 (5.6)	67 (9)
<i>Total</i>	449 (60)	237 (32)	58 (8)	744 (100)

IGCCCG = International Germ Cell Cancer Collaborative Group.

^a No reclassification would be observed for 575 men (green). Higher IGCCCG classification leading to overtreatment would be observed for 122 men (16%; red). Lower IGCCCG classification leading to undertreatment would be observed for 47 men (6%; yellow).




Fig. 1 – Kaplan-Meier curves for progression-free survival stratified by International Germ Cell Cancer Collaborative Group (IGCCCG) classification according to preorchietomy (PreORCH) or prechemotherapy (PreCHEM) marker levels. KME = Kaplan-Meier estimate; CI = confidence interval.

limited number of events in the small subgroups, we were not able to conduct any robust PFS analyses for the 169 men with IGCCCG group incorrectly assigned using preorchietomy STM levels (Fig. 1).

Increases in STM levels after orchietomy indicate that progressing metastases continue to excrete STMs into the circulation and are producing more STMs than the primary tumor that was removed. Thus, patients might move from the good to the intermediate or from the intermediate to the poor prognosis IGCCCG category after orchietomy and should be treated accordingly. By contrast, decreases in STM levels after orchietomy indicate that a considerable amount of STMs originated from the primary testicular tumor. Interestingly, approximately 10% of our cohort showed a STM decline according to STM half-life times (AFP ~6 d, HCG ~3 d, LDH ~1 d), which suggests that the primary testicular tumor and not metastases was the main contributor to STM expression. For men classified in the IGCCCG intermediate/poor prognosis groups who did not have any NPVM before orchietomy and experienced a decrease in STMs after surgery, repeated measurements before initiating chemotherapy could potentially reclassify them as having good IGCCCG prognosis. This reclassification is significant because patients who are categorized incorrectly as having intermediate/poor instead of good IGCCCG prognosis tend to receive overtreatment with four cycles

of BEP instead of three, leading to greater short- and long-term side effects of chemotherapy.

This study was an exploratory analysis of the largest metastatic GCC series, but the retrospective approach is an inherent limitation. Because data collection for the IGCCCG Update did not primarily address the question for the present analysis, our results include only a subset of patients with complete preorchietomy and postorchietomy STM data and may thus not be representative. In addition, this analysis does not apply to patients with a very high tumor load and/or life-threatening metastases who require immediate upfront chemotherapy and orchietomy after completion of first-line treatment.

Nevertheless, our results indicate that up to one in four men with metastatic GCC and no NPVM would be exposed to overtreatment or undertreatment if preorchietomy instead of prechemotherapy STM results were used for IGCCCG prognostic group assignment. This reinforces the recommendations in international guidelines. Prechemotherapy STM results remain the reference point for IGCCCG prognostic classification and should be clearly specified in national and international guidelines.

Author contributions: Jörg Beyer had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Fankhauser, Jandari, Collette, Gillessen, Beyer.
Acquisition of data: Fankhauser, Tandstad, Jiang, De Giorgi, Sweeney, Terbuch, Chovanec, Huddart, Bokemeyer.
Analysis and interpretation of data: Fankhauser, Jandari, Collette, Gillessen, Beyer.
Drafting of the manuscript: Fankhauser, Beyer, Gillessen.
Critical revision of the manuscript for important intellectual content: Collette.
Statistical analysis: Jandari, Collette.
Obtaining funding: Gillessen.
Administrative, technical, or material support: Collette, Gillessen.
Supervision: Beyer, Collette, Gillessen.
Other: None.

Financial disclosures: Jörg Beyer certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: This research was supported by grants and donations from the EORTC Genito-urinary Cancer Group, the Swiss Cancer Foundation and Movember Europe. A Jandari's work as Fellow at EORTC Headquarters was supported by a grant from the IGCCCG and the EORTC Cancer Research Fund (ECRF).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.euros.2023.08.008>.

References

- [1] International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol* 1997;15:594–603.
- [2] Gillessen S, Sauv  N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. *J Clin Oncol* 2021;39:1563–74.
- [3] Beyer J, Collette L, Sauv  N, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. *J Clin Oncol* 2021;39:1553–62.

^a Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland

^b European Organisation for Research and Treatment of Cancer, Brussels, Belgium

^c The Cancer Clinic, St. Olav's University Hospital and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

^d Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

^e IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy

^f Italian Germ Cell Cancer Group, Genoa, Italy

^g South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia

^h Division of Oncology, Medical University of Graz, Graz, Austria

ⁱ 2nd Department of Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia

^j Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

^k Department of Oncology, Hematology and BMT with Pneumology Section, University Hospital Hamburg-Eppendorf, Hamburg, Germany

^l Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland

^m Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland

ⁿ University of Southern Switzerland, Lugano, Switzerland

* Corresponding author. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland. Tel. +41 31 632 2243.

E-mail address: joerg.beyer@insel.ch (J. Beyer).